Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3223 | REGN10933+REGN10987 combination therapy Wiki | 0.41 |
| drug2916 | Placebo Wiki | 0.03 |
Navigate: Correlations HPO
There are 2 clinical trials
The study will evaluate the safety and efficacy of orally-administered M5049 in COVID-19 pneumonia participants who are hospitalized but not on mechanical ventilation.
Description: A nine point ordinal scale - 0: Uninfected No limitation of activities Limitation of activities Hospitalized, mild disease on, no oxygen therapy Hospitalized, with oxygen by mask or nasal prongs Hospitalized, severe disease: noninvasive ventilation or high flow oxygen Hospitalized, severe disease: intubation and mechanical ventilation Hospitalized, severe disease: ventilation plus additional organ support - example, vasopressors, Extracorporeal membrane oxygenation (ECMO) Death.
Measure: Clinical Status of Participants on a 9-Point Ordinal Scale Time: Day 1 through Day 60Description: Normal oxygen exchange in room air.
Measure: Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours on Room Air Time: Day 1 through Day 28Description: Percentage of Participants who die for any reason.
Measure: Percentage of Participants With All-Cause Mortality Time: Day 1 through Day 28Description: Clinical Deterioration
Measure: Clinical Deterioration: Time to Intensive Care Unit (ICU) Admission Time: Day 1 through Day 28Description: Clinical Deterioration
Measure: Clinical Deterioration: Time to Invasive Mechanical Ventilation Time: Day 1 through Day 28Description: Clinical Deterioration
Measure: Clinical Deterioration: Time to Non-Invasive Mechanical Ventilation Time: Day 1 through Day 28Description: Relapse refers to rehospitalization due to worsening oxygenation, with either a positive result of any respiratory pathogenic nucleic acid test, or worsening lesions on chest imaging.
Measure: Percentage of Participants With Relapse Time: Day 5 through Day 60Description: Percentage or participants who are re-hospitalized for any reason.
Measure: Percentage of Participants who are Re-Hospitalized Time: Day 5 through Day 60Description: Only the first 15 participants will be evaluated for Pharmacokinetic parameters.
Measure: Maximum Observed Concentration (Cmax) of M5049 Time: Day 1 and Day 7The study will evaluate the safety and efficacy of orally-administered M5049 in COVID-19 pneumonia participants who are hospitalized but not on mechanical ventilation.
Description: A nine point ordinal scale - 0: Uninfected No limitation of activities Limitation of activities Hospitalized, mild disease on, no oxygen therapy Hospitalized, with oxygen by mask or nasal prongs Hospitalized, severe disease: noninvasive ventilation or high flow oxygen Hospitalized, severe disease: intubation and mechanical ventilation Hospitalized, severe disease: ventilation plus additional organ support - example, vasopressors, Extracorporeal membrane oxygenation (ECMO) Death.
Measure: Clinical Status of Participants on a 9-Point Ordinal Scale Time: Day 1 through Day 60Description: Normal oxygen exchange in room air.
Measure: Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours on Room Air Time: Day 1 through Day 28Description: Percentage of Participants who die for any reason.
Measure: Percentage of Participants With All-Cause Mortality Time: Day 1 through Day 28Description: Clinical Deterioration
Measure: Clinical Deterioration: Time to Intensive Care Unit (ICU) Admission Time: Day 1 through Day 28Description: Clinical Deterioration
Measure: Clinical Deterioration: Time to Invasive Mechanical Ventilation Time: Day 1 through Day 28Description: Clinical Deterioration
Measure: Clinical Deterioration: Time to Non-Invasive Mechanical Ventilation Time: Day 1 through Day 28Description: Relapse refers to rehospitalization due to worsening oxygenation, with either a positive result of any respiratory pathogenic nucleic acid test, or worsening lesions on chest imaging.
Measure: Percentage of Participants With Relapse Time: Day 5 through Day 60Description: Percentage or participants who are re-hospitalized for any reason.
Measure: Percentage of Participants who are Re-Hospitalized Time: Day 5 through Day 60Description: Only the first 15 participants will be evaluated for Pharmacokinetic parameters.
Measure: Maximum Observed Concentration (Cmax) of M5049 Time: Day 1 and Day 7Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports